FDA Drug recall D-1839-2019
Eptifibatide Injection, 75 mg/100 mL (0.75 mg/mL), 100 mL Single-use Vial, For Intravenous Use Only, Rx Only, Manufactured by: Akorn, Inc.,…
- FDA Drug
- Class III
- terminated
- Published 2019-09-04
On 2019-09-04 the FDA classified a Class III recall of Eptifibatide Injection, 75 mg/100 mL (0.75 mg/mL), 100 mL Single-use Vial, For Intravenous Use Only, Rx Only, Manufactured by: Akorn, Inc.,… by Akorn, citing failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1839-2019 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2019-08-06 |
| Published | 2019-09-04 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Akorn |
| Distribution | US |
Product
Eptifibatide Injection, 75 mg/100 mL (0.75 mg/mL), 100 mL Single-use Vial, For Intravenous Use Only, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045, NDC 17478-903-90.
Reason
Failed Impurities/Degradation Specifications: Out of Specification (OOS) for known impurity, D-aspartic acid.
Identifiers
| code_info | Lot #s: 091287A, 091377A, Exp. 9/19. |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1839-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.